Cryptococcosis primary prevention: Difference between revisions
Jump to navigation
Jump to search
| Line 7: | Line 7: | ||
*Take the lowest doses of [[corticosteroid]] medications possible. | *Take the lowest doses of [[corticosteroid]] medications possible. | ||
*Practice safe sex to reduce the risk of getting [[HIV]] and the infections associated with a weakened immune system. | *Practice safe sex to reduce the risk of getting [[HIV]] and the infections associated with a weakened immune system. | ||
*[[Cryptococcosis|Cryptococcal]] meningitis commonly affects patients with [[CD4]] count are ≤ 100 cells/μl. It is responsible for major cause of [[mortality]] and [[morbidity]] in [[Human Immunodeficiency Virus (HIV)|HIV]] individuals. It is recommended that patients with [[CD4]] counts ≤ 100 cells/μl, should have routine [[Cryptococcosis|cryptococcal]] antigen screening. Patients with positive result are offered preemptive [[Antifungal drug|anti-fungal therapy]].<ref name="pmid28166254">{{cite journal| author=Cassim N, Schnippel K, Coetzee LM, Glencross DK| title=Establishing a cost-per-result of laboratory-based, reflex Cryptococcal antigenaemia screening (CrAg) in HIV+ patients with CD4 counts less than 100 cells/μl using a Lateral Flow Assay (LFA) at a typical busy CD4 laboratory in South Africa. | journal=PLoS One | year= 2017 | volume= 12 | issue= 2 | pages= e0171675 | pmid=28166254 | doi=10.1371/journal.pone.0171675 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28166254 }} </ref><ref name="pmid28134711">{{cite journal| author=Greene G, Sriruttan C, Le T, Chiller T, Govender NP| title=Looking for fungi in all the right places: screening for cryptococcal disease and other AIDS-related mycoses among patients with advanced HIV disease. | journal=Curr Opin HIV AIDS | year= 2017 | volume= 12 | issue= 2 | pages= 139-147 | pmid=28134711 | doi=10.1097/COH.0000000000000347 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28134711 }} </ref> | |||
==References== | ==References== | ||
Revision as of 18:27, 5 June 2017
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
|
Cryptococcosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Cryptococcosis primary prevention On the Web |
|
American Roentgen Ray Society Images of Cryptococcosis primary prevention |
|
Risk calculators and risk factors for Cryptococcosis primary prevention |
Overview
Primary Prevention
- Take the lowest doses of corticosteroid medications possible.
- Practice safe sex to reduce the risk of getting HIV and the infections associated with a weakened immune system.
- Cryptococcal meningitis commonly affects patients with CD4 count are ≤ 100 cells/μl. It is responsible for major cause of mortality and morbidity in HIV individuals. It is recommended that patients with CD4 counts ≤ 100 cells/μl, should have routine cryptococcal antigen screening. Patients with positive result are offered preemptive anti-fungal therapy.[1][2]
References
- ↑ Cassim N, Schnippel K, Coetzee LM, Glencross DK (2017). "Establishing a cost-per-result of laboratory-based, reflex Cryptococcal antigenaemia screening (CrAg) in HIV+ patients with CD4 counts less than 100 cells/μl using a Lateral Flow Assay (LFA) at a typical busy CD4 laboratory in South Africa". PLoS One. 12 (2): e0171675. doi:10.1371/journal.pone.0171675. PMID 28166254.
- ↑ Greene G, Sriruttan C, Le T, Chiller T, Govender NP (2017). "Looking for fungi in all the right places: screening for cryptococcal disease and other AIDS-related mycoses among patients with advanced HIV disease". Curr Opin HIV AIDS. 12 (2): 139–147. doi:10.1097/COH.0000000000000347. PMID 28134711.